CARLSBAD - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023).
The presentation, 'Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial' was presented by Eyal Banin, M.D., Ph.D., Director, Center for Retinal and Macular Degenerations, Department of Ophthalmology at Hadassah-Hebrew University Medical Center, on behalf of Roche and Genentech, a member of the Roche Group.
RG6501 (OpRegen) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD.
'We are extremely pleased to see our observations of improved retinal structure in the initial clinical study of OpRegen are being reinforced by additional external and independent analyses of the images performed by Genentech and Roche. Looking ahead, we are excited to collaborate with Genentech and Roche on the ongoing Phase 2a study of OpRegen, which is currently enrolling patients and open at multiple sites in the US, with more sites expected to come online this year,' stated Brian Culley, CEO of Lineage.
Dr. Banin added, 'I have been closely involved with the OpRegen program since its beginning and I continue to be excited about the potential therapeutic benefit for patients afflicted with dry AMD and geographic atrophy, a progressive and debilitating disease that significantly affects the quality of life of many. These data further highlight the potential for a single dose of OpRegen to provide significant clinical outcomes for patients in a disease with a tremendous unmet need.'
About OpRegen
OpRegen is a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration. Following subretinal delivery, OpRegen has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal structure and function. OpRegen is being developed under a worldwide collaboration between Lineage, Roche and Genentech, a member of the Roche Group.
About the Phase 1/2a Study
The Phase 1/2a study is an open-label, single-arm, multi-center, dose-escalation trial evaluating a single administration of OpRegen delivered subretinally in patients with bilateral GA. Twenty-four patients were enrolled into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with a best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 patients with impaired vision (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new 'thaw-and-inject' formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment-emergent adverse events. Secondary objectives are to evaluate the preliminary activity of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance.
About Geographic Atrophy
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterized by severe loss of visual function. GA is a leading cause of adult blindness in the developed world, affecting at least 5 million people globally. There are two forms of advanced AMD: neovascular AMD and GA. GA and neovascular AMD can occur simultaneously in the same eye, and patients treated for neovascular AMD may still go on to develop GA. GA typically affects both eyes.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic ('off-the-shelf') product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage's VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as 'believe,' 'aim,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'design,' 'intend,' 'expect,' 'could,' 'can,' 'plan,' 'potential,' 'predict,' 'seek,' 'should,' 'would,' 'contemplate,' 'project,' 'target,' 'tend to,' or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential therapeutic benefits OpRegen in patients with GA secondary to AMD; the significance of clinical data reported to date from the Phase 1/2a study of OpRegen, including the findings of retinal tissue restoration and visual function improvements and the potential utilization of OCT imaging to measure efficacy in a pivotal clinical trial of OpRegen. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice and those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading 'Risk Factors' in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contact:
Ioana C. Hone
Email: ir@lineagecell.com
Tel: (442) 287-8963
(C) 2023 Electronic News Publishing, source ENP Newswire
Read the original:
LINEAGE - RG6501 PHASE 1/2A CLINICAL RESULTS SUPPORT THE POTENTIAL FOR OPREGEN TO SLOW, STOP OR REVERSE DISEASE PROGRESSION IN GEOGRAPHIC ATROPHY...
- Hungarian Spinal Cord Injury Patient - Stem Cell Treatment Experience [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- Stem cell treatment for Spinal Cord Injury (SCI)-Osama [Last Updated On: May 8th, 2011] [Originally Added On: May 8th, 2011]
- Spinal Cord Injury Patient after Stem Cell Treatment - Juan Carlos Murillo [Last Updated On: May 10th, 2011] [Originally Added On: May 10th, 2011]
- Spinal Cord Injury patient 10 years after injury after Stem Cell Treatment [Last Updated On: May 10th, 2011] [Originally Added On: May 10th, 2011]
- Rap Toward a Cure for Spinal Cord Injury [Last Updated On: May 11th, 2011] [Originally Added On: May 11th, 2011]
- Christopher "Kit" Bond - Spinal Cord Injury Stem Cell Patient [Last Updated On: May 20th, 2011] [Originally Added On: May 20th, 2011]
- Stem Cell Treatment - Spinal Cord Injury (2) [Last Updated On: May 21st, 2011] [Originally Added On: May 21st, 2011]
- Spinal Cord Injury-After Treatment, Pt was completely paralyzed (2) [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- Spinal Cord Injury-After Treatment, Pt was completely paralyzed (1) [Last Updated On: May 23rd, 2011] [Originally Added On: May 23rd, 2011]
- Dogs recover following new treatment for spinal cord injury [Last Updated On: June 2nd, 2011] [Originally Added On: June 2nd, 2011]
- Spinal Cord Injury Rehabiliation Success Story [Last Updated On: June 3rd, 2011] [Originally Added On: June 3rd, 2011]
- Stem Cells for Spinal Cord Injury: Community Outreach San Diego 2011 - Trish Stressman [Last Updated On: June 7th, 2011] [Originally Added On: June 7th, 2011]
- Stroke Client Gains Strength and Mobility in North Palm Beach Florida [Last Updated On: June 9th, 2011] [Originally Added On: June 9th, 2011]
- Spinal Cord Injury Chicago Rehabilitation Lokomat [Last Updated On: June 10th, 2011] [Originally Added On: June 10th, 2011]
- Spinal Cord Injury Treatment With Stem Cells [Last Updated On: June 11th, 2011] [Originally Added On: June 11th, 2011]
- Spinal Cord Injury Patient after Stem Cell Treatment - Wesley Hixen [Last Updated On: June 12th, 2011] [Originally Added On: June 12th, 2011]
- Stem Cell Therapy for Spinal Cord Injury - Injured Airline Pilot Flies Again [Last Updated On: June 13th, 2011] [Originally Added On: June 13th, 2011]
- David Chen: How would stem-cell therapies work in the treatment of spinal cord injuries? [Last Updated On: June 17th, 2011] [Originally Added On: June 17th, 2011]
- William Rader MD - Paralyzed Spinal Cord Injury Patient Walks Again [Last Updated On: June 29th, 2011] [Originally Added On: June 29th, 2011]
- The Spinal Cord Injury Treatment Team [Last Updated On: July 4th, 2011] [Originally Added On: July 4th, 2011]
- Introduction to the Bioness H200 Hand Rehabilitation System [Last Updated On: July 14th, 2011] [Originally Added On: July 14th, 2011]
- Organ repair using own stem cells -- brain, heart - Future Health keynote speaker [Last Updated On: July 15th, 2011] [Originally Added On: July 15th, 2011]
- 2011 Shriners Ride for Kids, Salt Lake City Utah. [Last Updated On: July 17th, 2011] [Originally Added On: July 17th, 2011]
- Degenerative Disc Disease: C5-C6 c6-C7 Treatment [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- Rehabilitation Institute of Michigan's 60 Anniversary TV Commercial [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- California Spinal Cord Injury Attorney: Obtaining damages for lifetime care. [Last Updated On: July 19th, 2011] [Originally Added On: July 19th, 2011]
- Physical and Mental Adjustments After a Spinal Cord Injury [Last Updated On: July 19th, 2011] [Originally Added On: July 19th, 2011]
- Comprehensive Inpatient Rehabilitation [Last Updated On: July 28th, 2011] [Originally Added On: July 28th, 2011]
- SCI Treatment Center at the Claremont Club [Last Updated On: July 30th, 2011] [Originally Added On: July 30th, 2011]
- Spinal Cord Inury Patient at XCell-Center- M. Hasan [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- Spinal Cord Inury Patient at XCell-Center- K. Potts [Last Updated On: August 6th, 2011] [Originally Added On: August 6th, 2011]
- Magee Rehabilitation Hospital Foundation and Toyota 100 Cars for Good [Last Updated On: August 13th, 2011] [Originally Added On: August 13th, 2011]
- SCI_Celine_French_ifting_her_arms.wmv [Last Updated On: September 1st, 2011] [Originally Added On: September 1st, 2011]
- New Treatment May Help Paralyzed Patients Move Again By Dr.Zaghloul ahmed [Last Updated On: September 1st, 2011] [Originally Added On: September 1st, 2011]
- Claire Marsh - Spinal Cord Injury Part One [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Coping with spinal cord and traumatic brain injuries [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Stem Cell Treatment - Spinal Cord Injury (3) [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Stem Cell Treatment - Spinal Cord Injury (1) [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Stem cell treatment by Adiva Health Care India after Spinal Cord Injury [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- Spinal Cord Injury Documentary: You Will Never Walk Again, Part 1 [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Claire Marsh Returns - Spinal Cord Injury Patient [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Spinal Cord Injury: Raising awareness about research and treatment for spinal cord injury [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Walking after Spinal Cord injury and Stem Cells [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- New Treatments for Spinal Cord Injuries [Last Updated On: October 10th, 2011] [Originally Added On: October 10th, 2011]
- Claire Marsh - Spinal Cord Injury Part Two - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Stem Cell Treatment for Spinal Cord Injury - Video [Last Updated On: November 2nd, 2011] [Originally Added On: November 2nd, 2011]
- Stem Cells - Treatment for Spinal Cord Injury - Video [Last Updated On: November 2nd, 2011] [Originally Added On: November 2nd, 2011]
- (Film Trailer) - The Spinal Cord Journey: Stem Cell Therapy Stories of Recovery - Video [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- Stem Cell Treatment for T-6 Spinal Cord Injury - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- What is Project Walk Atlanta - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Stem Cells Treatment for Spinal Cord Injuries, Successfully Results, Stem Therapy - Video [Last Updated On: December 28th, 2011] [Originally Added On: December 28th, 2011]
- Stem Cell Therapy for Spinal Cord Injury, India Mumbai - Video [Last Updated On: January 6th, 2012] [Originally Added On: January 6th, 2012]
- "April Crave", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 10th, 2012] [Originally Added On: January 10th, 2012]
- "Lori Hammond", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 23rd, 2012] [Originally Added On: January 23rd, 2012]
- "Chad C.""spinal cord Injury treatment" "spinal cord injury" "spinal cord injury recovery" - Video [Last Updated On: January 23rd, 2012] [Originally Added On: January 23rd, 2012]
- "Hugo Rodovalho", "Client Spotlight Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- "Cecilia V.", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- "Roy R.", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- "Angela", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- "Joey's Story", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- "Spinal Cord Injury", "A Story Of One" - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- Spinal Cord Injuries - The Healing Center Project! - Video [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- "Crystal H.", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- "Dave D.", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- "Brook", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- "Ashley Vargas", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 6th, 2012] [Originally Added On: February 6th, 2012]
- "Nathan Bayer", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- "Annette Ross", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- "Joe Guintu", "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- "Trevor Comeau,"Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 9th, 2012] [Originally Added On: February 9th, 2012]
- "Kyle Eade, "Project Walk Spinal Cord Injury Recovery" - Video [Last Updated On: February 11th, 2012] [Originally Added On: February 11th, 2012]
- Velomedix Receives IDE Approval to Evaluate the Use of Rapid Therapeutic Hypothermia in the Management of AMI Patients [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Neuralstem Announces Closing of $5.2-Million Registered Direct Offering [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Chamber May Open Window for Treating Spine [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on Fox News First and San Antonio Living [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- High doses of 'load' slows loss of bone in spinal cord injury [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- InVivo Therapeutics Announces Pricing of Public Offering of Common Stock [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- High Doses of Load Slows Bone Loss in Spinal Cord Injury [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- InVivo Therapeutics Announces Full Exercise of Over-Allotment Option [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- InVivo Therapeutics Announces Net $18.1M In Offering [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]